This technology includes the use of the combination of the compounds Chroman-1 and Emricasan to achieve virtually 100% cell survival during human pluripotent stem cell passaging, cryopreservation/thawing, and differentiation in 2D and 3D cultures. Human pluripotent stem cells, including ESCs and iPSCs, are highly sensitive cells and undergo apoptosis during these routine procedures. A screening approach was used to identify the combination of the two compounds in this invention. The compounds allow dosing at a relatively low concentration, thus providing a cheaper iPSC growth media, stress-free environment, and minimization of off-target effects.
This invention will significantly improve quality assurance, characterization, and application of pluripotent stem cells in both pre-clinical and clinical settings.
The combination of the compounds Chroman-1 and Emricasan permit a higher cell survival rate for pluripotent and differentiating cells compared to commonly used procedures.